TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Alvotech ( (ALVO) ).
On November 20, 2025, Alvotech, in partnership with Advanz Pharma, announced that their biosimilar product Gobivaz®, a version of Simponi® (golimumab), received marketing approval from the European Commission for use in the European Economic Area. This approval marks a significant milestone as Gobivaz® is the first biosimilar to Simponi® approved in Europe, enhancing Alvotech’s commercial presence in the region and expanding access to biologic medicines for immune-mediated diseases. The approval is based on comprehensive analytical and clinical data, further solidifying Alvotech’s position in the biosimilar market.
The most recent analyst rating on (ALVO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Underperform.
Alvotech’s overall stock score is primarily impacted by its financial instability, with high leverage and declining revenue growth posing significant risks. Technical analysis further indicates bearish momentum, while valuation metrics suggest potential overvaluation. Despite strategic investments and growth potential, regulatory and operational challenges weigh heavily on the stock’s outlook.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines for patients worldwide. The company aims to be a leader in the biosimilar industry by delivering high-quality, cost-effective products and services. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has established strategic commercial partnerships across various global markets.
Average Trading Volume: 500,245
Technical Sentiment Signal: Sell
Current Market Cap: $1.58B
For an in-depth examination of ALVO stock, go to TipRanks’ Overview page.